# Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

> **NCT02315612** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 134 (actual)

## Conditions studied

- NHL
- Large Cell Lymphoma
- Follicular Lymphoma
- ALL
- B-All
- B-precursor ALL
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- B-Non Hodgkin Lymphoma
- B-NHL

## Interventions

- **BIOLOGICAL:** CD22-CAR

## Key facts

- **NCT ID:** NCT02315612
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-12
- **Primary completion:** 2019-04-03
- **Final completion:** 2024-10-29
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315612, "Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02315612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*